European Long-acting Antipsychotics in Schizophrenia Trial (EUlast) | C4C

The EULAST trial is a large European scientific study to gather information on the potential benefits as well as the side effects of two relatively recently introduced medicines used for the treatment of schizophrenia. This trial hopes to recruit patients with a diagnosis of schizophrenia for whom a medication switch is clinically indicated. Participants would be randomised to either an oral antipsychotic (paliperidone or aripiprazole) or a depot antipsychotic (paliperidone palmitate or Abilify Maintena). They would then be followed up by the research team on a monthly basis for up to 18 months, to monitor their mental state, cognition and quality of life; and to identify reasons for stopping medication. The study will allow us to assess the advantages and disadvantages of prescribing these medicines as either tablets or regular injections. A total of 600 patients with psychosis are expected to participate in this study. We hope to recruit up to 5 participants in Slam.